TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28976844
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at site Y (over the midpoint)
Study: 23687948
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin aspart with NPH insulin
Study: 23687948
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin with NPH insulin
Study: 19824222
Drug: Tesofensine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine 0.25 mg
Study: 19824222
Drug: Tesofensine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesofensine 0.5 mg
Study: 16648042
Drug: CHOP-like chemotherapy
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-like chemotherapy alone (n=411)
Study: 16648042
Drug: CHOP-like chemotherapy
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-like chemotherapy plus rituximab (n=413)
Study: 2741997
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment
Study: 10915096
Drug: Women (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women (adjusted for CD4 T cell count, race or ethnicity, injection drug use, and age)
Study: 9816176
Drug: Methotrexate/cytarabine infusions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate/cytarabine infusions, n = 69 (low-risk) and n = 248 (all risk groups)
Study: 26526160
Drug: PULSE Program
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PULSE Program (self-administered lifestyle intervention)
Study: 17261285
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg ethinyl‐E(2) (EE) three times a day for 2 weeks
Study: 11345387
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 mg/kg) plus four additional intravenous doses over 24 h
Study: 9338902
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline placebo
Study: 3071617
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CTX) + Fosfomycin (FOM) administration
Study: 3071617
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (CTX) single administration
Study: 31983281
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day AXOS for 12 weeks
Study: 28365464
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group therapy (MGT)
Study: 29180593
Drug: Self-help treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatments (including painkillers)
Study: 29180593
Drug: Steam inhalation
Normalized name: Leader Hot Steam Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam inhalation
Study: 27045520
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) + group cognitive behavioral therapy (gCBT)
Study: 27045520
Drug: Befriending +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befriending + group cognitive behavioral therapy (gCBT)
Study: 11774112
Drug: High-dose sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sequential vitamin B6 and folic acid supplementation
Study: 26803590
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 treatment
Study: 1674294
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226)
Study: 1674294
Drug: Controlled-protein diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-protein diet (1.0 g/kg daily; n = 230)
Study: 1674294
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group A
Study: 1674294
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg body weight daily; n = 226) in group B
Study: 7022214
Drug: Maintenance doses
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance doses of vinblastine
Study: 21310305
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g of mixed fibers
Study: 21310305
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of mixed fibers
Study: 9804219
Drug: Micronized 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐oestradiol 4 mg/day with GnRHa suppression
Study: 9804219
Drug: Micronized 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐oestradiol 6 mg/day without GnRHa suppression
Study: 8014529
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 mL, IM (Control)
Study: 2809913
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D2 supplementation (2000 IU/day)
Study: 30371146
Drug: 1,500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg/day of GRE for 3 days
Study: 30641348
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with antidepressants
Study: 30641348
Drug: Internet based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet based cognitive‐behavioral therapy
Study: 22807519
Drug: Balapiravir 3000
Normalized name: Balapiravir
DrugBank: Balapiravir (DB12283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balapiravir 3000 mg
Study: 10661337
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with 5-fluorouracil (5-FU) and local-regional radiation
Study: 8097214
Drug: Alpidem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (25 mg twice daily during tapering)
Study: 20660284
Drug: Hesperidin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin (800 mg/day)
Study: 20660284
Drug: Naringin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin (500 mg/day)
Study: 15777866
Drug: Functional recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional recovery (defined in terms of neck pain intensity or work disability without medication use)
Study: 8622107
Drug: Isepamicin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 7.5 mg/kg twice daily
Study: 8622107
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg twice daily
Study: 31389210
Drug: Topical Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyclosporine Nanoemulsion 0.05% (CN)
Study: 31389210
Drug: Topical Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cyclosporine Emulsion 0.05% (CE)
Study: 25418605
Drug: Single-dose nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nilotinib 600 mg with midazolam 4 mg
Study: 2420106
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH)
Study: 19375008
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral anticoagulation therapy (OAT)
Study: 8157552
Drug: Famciclovir 125
Normalized name: famciclovir 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 125 mg
Study: 8157552
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg
Study: 7778840
Drug: Famciclovir 750
Normalized name: famciclovir 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 750 mg
Study: 16163627
Drug: Famciclovir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir (all doses)
Study: 3064772
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments in the DBCG programme
Study: 31675437
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g probenecid (PRO) + 600 mg tenofovir disoproxil fumarate (TDF) / 400 mg emtricitabine (FTC)
Study: 28444112
Drug: Vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (960 mg twice a day)
Study: 26178731
Drug: 1350 mg
Normalized name: HOMOSALATE 3060 mg in 45 mL / OCTOCRYLENE 4500 mg in 45 mL / OCTISALATE 2250 mg in 45 mL / AVOBENZONE 1350 mg in 45 mL TOPICAL CREAM [ZO Skin Health Daily Sheer Broad-Spectrum Sunscreen SPF 50 Water Resistant (40 Minutes)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1350 mg encapsulated green tea extract (540 mg GTC) with 50 mg vitamin C, twice daily for 3 months
Study: 9247776
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 3 months
Study: 23946601
Drug: Double-dose rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose rabeprazole (20 mg twice daily)
Study: 23946601
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amitriptyline + rabeprazole
Study: 23946601
Drug: Double-dose rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose rabeprazole
Study: 22118751
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplementation (640 mg polyphenols/d)
Study: 16989023
Drug: Pegaptanib (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaptanib (0.3 mg injected into the eye every 6 weeks)
Study: 12925219
Drug: NG‐methyl‐L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐methyl‐L‐arginine
Study: 9296229
Drug: Modified MIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified MIC regimen (cisplatin 100 mg/m2 on day 2, ifosfamide on day 1 with mitomycin)
Study: 21175545
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (BPS) 120 µg/day
Study: 18410283
Drug: Midodrine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (12.5 mg three times per day for 2 days)
Study: 23842215
Drug: Albumin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (8 g/L of removed ascites)
Study: 12887341
Drug: Oral‐B40+ manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B40+ manual brush
Study: 7031187
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 mg)
Study: 10189005
Drug: Beta-blocker withdrawal
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker withdrawal (24 hours after discontinuation of metoprolol)
Study: 7749881
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg
Study: 6342354
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus dipyridamole (400 mg/day)
Study: 6342354
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin (500 mg/day)
Study: 30496458
Drug: Rifampicin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (with peak concentration above 7 mg/L)
Study: 17470017
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment in group 2 (266 patients)
Study: 9854159
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current (IFC) applied prior to UV treatment
Study: 9854159
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current (IFC) applied in combination with UV-radiation
Study: 9854159
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current (IFC) applied after UV treatment
Study: 7875472
Drug: midazolam (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (35 micrograms/kg) and lidocaine spray (100 mg)
Study: 213498
Drug: CP-20,961 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-20,961 administered prior to challenge
Study: 213498
Drug: CP-20,961 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-20,961 administered 24 hours after challenge
Study: 213498
Drug: CP-20,961 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-20,961 administered 48 hours after challenge
Study: 15502972
Drug: D-cycloserine 50
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 50 mg/day
Study: 8719441
Drug: Gn-RHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gn-RHa plus hGH therapy
Study: 2624987
Drug: Other medical
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medical treatment (Control)
Study: 24948702
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment
Study: 23161357
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% (1 ml kg(‐1); Group B)
Study: 23161357
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus dexmedetomidine (1 μg kg(‐1); Group BD)
Study: 21810198
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group discussed self-efficacy scores using the Long-Term Medication Behaviour Self-Efficacy Scale (LTMBSES)
Study: 7717598
Drug: Dapsone-pyrimethamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone-pyrimethamine (100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly)
Study: 2288407
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg famotidine
Study: 27863271
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal oral pill (30mcg ethinyl estradiol and 150mcg levonorgestrel for 84 days)
Study: 24696010
Drug: UV‐A1 phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV‐A1 phototherapy (50 J/cm²) performed 4 times weekly for 3 months
Study: 22978309
Drug: Cineole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cineole (200 mg, three times per day for 6 months)
Study: 19274793
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with trace elements (TEs)
Study: 19274793
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (all groups)
Study: 17525141
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose >8 mmol/l) in non-lacunar stroke
Study: 11907944
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol delivery system A (twice a week)
Study: 2518857
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg o.m.)
Study: 8023719
Drug: Histamine H2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2-receptor antagonists (cimetidine 400 mg q.d.s. or ranitidine 150 mg b.d.)
Study: 12107216
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d)
Study: 19269130
Drug: Vaccine Safety
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Safety Messages (VSM)
Study: 19269130
Drug: Vaccine Information
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Information Statement (VIS)
Study: 1522839
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of mifepristone
Study: 7947424
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 micrograms with morphine 0.25 mg
Study: 7947424
Drug: Sufentanil 10
Normalized name: SUFentanil 100 MCG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 10 micrograms with morphine 0.25 mg
Study: 22028938
Drug: Killed whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-cell oral cholera vaccine (OCV)
Study: 26155841
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment navigators
Study: 24011635
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (newly developed lamivudine tablet)
Study: 21119152
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment model
Study: 16096182
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate lotion
Study: 16096182
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate emollient cream
Study: 15898289
Drug: Lotion vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion vehicle
Study: 10821298
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral oestrogen (1 mg, 17-beta-estradiol)
Study: 10821298
Drug: Oestrogen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen (1 mg 17-beta-estradiol) in combination with low-dose (0.5 mg) continuous norethisterone acetate (NETA)
Study: 10821298
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Low-dose oral oestrogen)
Study: 9007160
Drug: Acyclovir (dose-dependent)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (dose-dependent)
Study: 31410633
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) at therapeutic doses
Study: 7531032
Drug: Electrostatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostatic therapy (EST) with low voltage (200 to 1200 V)
Study: 7531032
Drug: Electrostatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostatic therapy (EST) with high voltage (500 to 2500 V)
Study: 1906610
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 micrograms twice daily
Study: 27444426
Drug: Interviewer-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administration of the TAPS Tool
Study: 27444426
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the TAPS Tool
Study: 19456308
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (MDZ) 5 mg
Study: 2190897
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg b.i.d. p.o. for ten days
Study: 2190897
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg b.i.d. p.o. for ten days
Study: 30918030
Drug: High-intensity intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity intervention programme (weekly group sessions for 12 months)
Study: 22496767
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (3 mg kg(‐1); AM(CAFF) trial)
Study: 9699585
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg intravenously before bypass and 33 mg/hr infusion after operation until the fifth postoperative day
Study: 9699585
Drug: Conventional perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional perioperative therapy
Study: 8137335
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg/day) plus retinyl palmitate (25,000 IU/day)
Study: 2802363
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment with one of three different fixed drug combinations containing isoniazid
Study: 108043
Drug: Ethane-1-hydroxy-1,1-diphosphonate (EHDP)
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethane-1-hydroxy-1,1-diphosphonate (EHDP) 4.4 mmol daily for 12 months
Study: 108043
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 12 months of EHDP treatment
Study: 108043
Drug: EHDP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHDP treatment
Study: 6385229
Drug: Azathioprine/steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine/steroids
Study: 21570352
Drug: Taxane-based regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based regimen (T-ET): three cycles of docetaxel 100 mg/m² followed by three cycles of intravenous epirubicin 90 mg/m² and docetaxel 75 mg/m².